Acute kidney injury (AKI) is a life-threatening disease that has no obvious symptoms in the early stages. Early identification of patients with AKI is one of the most critical unmet needs of physicians in their daily clinical practice. The focus of this article is on functional kidney biomarkers since it is not possible for damage markers to estimate the glomerular filtration rate (GFR).
During the 4th Scientific Symposium held near Potsdam, Germany, international medical experts discussed the latest developments in diagnostic and therapeutic innovations for advancing precision medicine in critically ill patients.
In a Private Wealth cover story, Dr. Andreas Bergmann shares his vision and progress towards developing new diagnostics and drugs for diseases that are recognized as global health burdens, such as sepsis.
Acute Kidney Injury is affecting 1 in 3 Intensive Care Unit (ICU) patients and the current standard of care diagnostics has considerable sensitivity and specificity limitations, there is an urgent need to implement new biomarkers to assist a better management of AKI.
The latest consensus meeting of international experts in critical care and nephrology supports the use of novel biomarkers in the prevention and management of Acute Kidney Injury (AKI). Read more in the following article.
Die Uniklinik RWTH Aachen und die SphingoTec GmbH („SphingoTec“) gaben heute bekannt, dass sie ihre Zusammenarbeit mit der Implementierung der neuen Biomarker in der klinischen Routine weiter ausgebaut haben.
Diagnostics company SphingoTec GmbH announced the launch of its IB10 sphingotest bio-ADM, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM).
Diagnostics company SphingoTec GmbH ("SphingoTec") today announced the launch of its IB10 sphingotest® bio-ADM®, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM®).
Experts representing European medical centers agreed that novel biomarkers are required for triaging and monitoring of these patients to optimally make use of the available medical resources and improve outcomes.
High blood levels of Dipeptidyl Peptidase 3 (DPP3) indicate the upcoming multiple organ failure and death in burn patients, as announced by the Diagnostics company SphingoTec GmbH and 4TEEN4 Pharmaceuticals GmbH.
High blood concentrations of the biomarker DPP3, previously described as an indicator of massive cell death and inflammation, has been shown to be associated with organ failure fatal outcomes in patients with severe burns.
Proenkephalin (PENK) is a novel candidate biomarker for kidney function that is filtrated in the glomerulus, shown to represent steady-state GFR in patients with different severities of renal insufficiency and is reliably predictive for acute kidney injury in patients with severe burns.
Bioactive Adrenomedullin is a biomarker for endothelial dysfunction and allows the prediction of septic shock as elevated blood levels of bio-ADM® predict blood pressure break down and blood vessel leakage resulting in edema
Diagnostics company SphingoTec GmbH have announced the launch of its IB10 sphingotest® penKid®, a CE-IVD-marked point-of-care test for Proenkephalin (penKid®), the biomarker that allows real-time assessment of kidney function with a simple blood test. Read the full article here.